FierceBiotechCodex · 实盘不做把握 5/10
北京时间·🕒 发布 20:14:00时区推断·⟳ 抓取 21:24:02·⚡ 决策 07-23 21:32:39 +8m37s·95.9 天前
罗氏诊断上半年销售按固定汇率仅增3%，中国医疗定价改革继续拖累亚太业务
罗氏诊断2026年上半年销售67.3亿瑞郎，固定汇率增长3%，但按瑞郎口径下降3%，属于大型药械公司的低增长确认。
📄 原文FierceBiotech↗ 原文
Roche Diagnostics growth remains muted amid China headwinds
Roche’s Diagnostics division continues to battle growth headwinds, notching a 3% increase in sales. For the first half…
不做 罗氏（ROG.CH）
大型公司分部财报解读，负面增量有限且可能已随业绩披露定价，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 媒体基于罗氏财务材料报道诊断业务上半年销售和中国拖累情况。
关键理由
- 罗氏诊断2026年上半年销售67.3亿瑞郎，固定汇率增长3%，但按瑞郎口径下降3%，属于大型药械公司的低增长确认。
- 亚太诊断销售固定汇率下降5%，Near Patient Care收入下降5%、Liat系统下降20%，说明中国定价改革和部分产品线仍拖累增长。
主要风险
- 这是罗氏集团内诊断业务的阶段性财务披露，对超大市值主标的短线冲击有限，且不是新的公司级突发暴雷。
原文全文
展开原文 · 1,467 字
Roche’s Diagnostics division continues to battle growth headwinds, notching a 3% increase in sales.
For the first half of 2026, the Swiss major reported sales of 6.73 billion Swiss francs ($7.78 billion), representing growth of 3% at constant exchange rates, though sales fell 3% when reported in Swiss francs.
That keeps growth relatively stagnant for the company, which posted a 2% revenue increase at constant exchange rates for full-year 2025. Sales also fell 3% when reported in Swiss francs.
The major issue continues to be China’s healthcare pricing reforms. The country’s approach has changed how medical devices and certain diagnostic services are paid for in response to what officials viewed as high prices.
Roche said diagnostics sales in the Asia-Pacific region decreased 5% at constant exchange rates, an improvement from the 12% decline recorded for 2025. Sales increased in every other region, with Latin America’s 10% jump representing the strongest geographic growth.
Across Roche’s Diagnostics units, Pathology Lab remained the division’s biggest growth driver, with sales up 11% at constant exchange rates. Core Lab and Molecular Lab sales increased 4% and 3%, respectively, during the first six months.
Near Patient Care, however, continued to weigh on sales, with revenue down 5%. The Liat system, Roche’s molecular point-of-care diagnostics platform, was the biggest drag, with sales down 20%, according to the company’s financial presentation.
For the first half of 2026, the Swiss major reported sales of 6.73 billion Swiss francs ($7.78 billion), representing growth of 3% at constant exchange rates, though sales fell 3% when reported in Swiss francs.
That keeps growth relatively stagnant for the company, which posted a 2% revenue increase at constant exchange rates for full-year 2025. Sales also fell 3% when reported in Swiss francs.
The major issue continues to be China’s healthcare pricing reforms. The country’s approach has changed how medical devices and certain diagnostic services are paid for in response to what officials viewed as high prices.
Roche said diagnostics sales in the Asia-Pacific region decreased 5% at constant exchange rates, an improvement from the 12% decline recorded for 2025. Sales increased in every other region, with Latin America’s 10% jump representing the strongest geographic growth.
Across Roche’s Diagnostics units, Pathology Lab remained the division’s biggest growth driver, with sales up 11% at constant exchange rates. Core Lab and Molecular Lab sales increased 4% and 3%, respectively, during the first six months.
Near Patient Care, however, continued to weigh on sales, with revenue down 5%. The Liat system, Roche’s molecular point-of-care diagnostics platform, was the biggest drag, with sales down 20%, according to the company’s financial presentation.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。